ロード中...
Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus
Canagliflozin (Invokana) is an innovative treatment for type 2 diabetes mellitus (DM) approved in a new class acknowledged as sodium-glucose co-transporter 2 inhibitors. Acute pancreatitis is a very rare side effect with an incidence <1%. a 50-year-old white male with DM type 2 presented to the e...
保存先:
| 出版年: | J Basic Clin Pharm |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Medknow Publications & Media Pvt Ltd
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4513334/ https://ncbi.nlm.nih.gov/pubmed/26229348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0976-0105.160753 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|